Today: 17 January 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Why Rush Street Interactive (RSI) stock is down today: Zacks downgrade to “hold”

Why Rush Street Interactive (RSI) stock is down today: Zacks downgrade to “hold”

NEW YORK, December 31, 2025, 12:46 ET — Regular session. Rush Street Interactive, Inc. shares were down 3.6% on Wednesday after Zacks Research downgraded the online-gambling operator to “hold,” MarketBeat reported. The stock was down 72.5 cents at $19.39 by 12:46 p.m. ET after trading between $19.36 and $20.27, on about 318,000 shares. MarketBeat said the stock still carries a…
31 December 2025
····
Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

NEW YORK, December 31, 2025, 11:55 ET — Regular session Shares of Cogent Biosciences slid on Wednesday, paring losses from earlier in the session, after the biotech disclosed a key regulatory filing while investors digested a cluster of insider stock sales. The stock was down 2.5% at $36.19, after touching a low of $34.33. The move comes as Cogent shifts…
31 December 2025
····
AAON stock slips even after credit line boost to $600 million — what Wall Street is watching next

AAON stock slips even after credit line boost to $600 million — what Wall Street is watching next

NEW YORK, Dec 31, 2025, 12:20 ET — Regular session. AAON shares were down 2.7% at $76.48 in midday trade on Wednesday, after touching $79.67 earlier in the session. The move came two days after AAON disclosed it increased borrowing capacity on its existing credit facility to $600 million by exercising a previously available $100 million “accordion” feature — an…
31 December 2025
····
BKV stock slides as natural gas tumbles again — what traders are watching next

BKV stock slides as natural gas tumbles again — what traders are watching next

NEW YORK, December 31, 2025, 12:25 PM ET — Regular session BKV Corp shares slipped on Wednesday as the latest leg lower in U.S. natural gas prices weighed on sentiment across gas-linked producers. The stock was down about 2.6% at around $27.10 in midday trading, after touching $27.00. Why it matters now: natural gas has been driving the near-term tape…
31 December 2025
····
MIAX slides as year-end trading thins — what traders are watching next

MIAX slides as year-end trading thins — what traders are watching next

NEW YORK, December 31, 2025, 12:19 ET — Regular session. Miami International Holdings, Inc. shares were down 2.2% on Wednesday midday, a softer tape in thin, year-end trading for the exchange operator. The stock last traded at $44.70, down $0.99 from the previous close, after moving between $44.05 and $46.00 in the session. (Marketwatch) MarketWatch Why it matters now: MIAX…
31 December 2025
···
Regencell Bioscience (RGC) stock slides nearly 5% in year-end trading as volatility persists

Regencell Bioscience (RGC) stock slides nearly 5% in year-end trading as volatility persists

NEW YORK, December 31, 2025, 11:51 ET — Regular session Regencell Bioscience Holdings Limited shares were down 4.8% at $21.79 as of 11:51 a.m. ET, after trading between $21.44 and $23.11 in a choppy session. The move came without any new company announcements. Regencell’s investor-relations site lists its most recent press release dated Oct. 31, and the latest SEC filing…
31 December 2025
···
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

NEW YORK, December 31, 2025, 11:38 ET — Regular session Genmab A/S (GMAB) shares slid on Wednesday, down about 3.3% at $30.44 in New York trading, as investors weighed a late-stage pipeline cut and the closing steps of a major acquisition. The Nasdaq-listed ADR touched $30.36 after opening at $31.42. Genmab said on Dec. 29 it will discontinue further clinical…
31 December 2025
···
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

NEW YORK, December 31, 2025, 11:19 ET — Regular session Abivax Société Anonyme’s U.S.-listed American depositary shares (ABVX) fell about 3.8% to $133.04, down roughly $5.30 from Tuesday’s close, in late morning trade on Wednesday. The shares opened at $138 and swung between $132.13 and $140.25, with about 348,000 shares traded. The pullback keeps the spotlight on ABVX after takeover…
31 December 2025
···
Nasdaq Keeps PLTS Trading Halted With No Reason Listed as Bengaluru ‘My Room, My Rules’ Row Spreads Online

Nasdaq Keeps PLTS Trading Halted With No Reason Listed as Bengaluru ‘My Room, My Rules’ Row Spreads Online

NEW YORK, December 31, 2025, 11:28 ET Nasdaq kept trading in Platinum Analytics Cayman Limited (PLTS) halted on Wednesday, with the reason listed as “not available” as of 10:23 a.m. ET, according to a Reuters market notice. TradingView The halt matters because it prevents investors from buying or selling the shares while they wait for clarity, a bigger issue in…
31 December 2025
·
1 … 209 210 211 212 213 … 629

Stock Market Today

  • Willis Towers Watson Valuation Post-Move: Fair Value Around $369 vs $329 Close
    January 17, 2026, 1:17 PM EST. Willis Towers Watson (WTW) drew fresh attention after a recent price move. The stock closed at $329.41. The one-day gain was 0.28%, with a year-to-date return of 0.96% and five-year TSR of 70.38%, suggesting longer-term momentum. A fair-value view places WTW at about $369.16 per share, implying the stock is undervalued relative to current levels. The market trades at a P/E ratio of 14.9x, above the US Insurance sector 12.8x but below the peer average of 29.5x, signaling limited further upside if earnings slip. The case rests on growth in advisory demand, recurring fee streams, and higher earnings in the mid-term, supported by disciplined costs, divestitures, and investments in high-growth regions. Risks include tougher competition, integration costs, and margin pressures.
Go toTop